Overview

Relative Bioavailability of 2 Oral Formulations of Nintedanib

Status:
Completed

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

To establish the bioequivalence of 1 soft gelatine capsule containing 200 mg nintedanib compared to 2 soft gelatine capsules containing 100 mg nintedanib

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Nintedanib